We are looking for 2019 Fiercest Women in Life Sciences

Its becoming a familiar refrain- Women are making headway in the workplace. In 2019, more women are serving in Congress than ever before, and various industries the life sciences included are well into implementing programs to boost diversity. Hows pharma doing. By one measure, pretty well. The biggest pharma companies on the London Stock Exchange nearly tripled the number of women on their executive committees between 2018 and 2019. But that sort of progress didn't extend to all top job titles, and some long-familiar challenges for women remain—in the industry and without. Take the U.S. national women’s soccer team, which has been petitioning its governing body for equal pay even as it wins more championships and brings in more revenue than the men’s team. Its players sued U.S. Soccer in March for years of “institutionalized gender discrimination,” three years after a wage discrimination complaint filed with the Equal Employment Opportunity Commission went nowhere. Things don’t look much better for women in the corporate world overall. In its latest “Women Count” report, which studies the 350 largest companies trading on the London Stock Exchange, U.K. gender diversity business The Pipeline found that a measly 3.7% of companies had a female CEO—down from 4.6% in 2017—and that more than 85% had no female executives on their boards. One of those companies was GlaxoSmithKline with its CEO, Emma Walmsley. And pharma companies did a little better than their peers within their executive committees. Pharma's Financial Times Stock Exchange companies almost tripled female representation on exec committees to 26% from 9% in 2018.